articleTop 10% cited

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

Urology · 1996 · Vol. 48(2) · pp. 326–334

George L. Wright✉(NewYork–Presbyterian Hospital)B. Mayer Grob(NewYork–Presbyterian Hospital)Cara Haley(NewYork–Presbyterian Hospital)Katie Grossman(NewYork–Presbyterian Hospital)Kathy Newhall(NewYork–Presbyterian Hospital)Daniel P. Petrylak(Eastern Virginia Medical School)John K. Troyer(NewYork–Presbyterian Hospital)Alice M. Konchuba(NewYork–Presbyterian Hospital)Paul F. Schellhammer(NewYork–Presbyterian Hospital)Richard P. Moriarty(Eastern Virginia Medical School)

View via DOI Publisher page

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Hormonal and reproductive studiesMedicineAndrogen deprivation therapyDownregulation and upregulationProstate-specific antigenGlutamate carboxypeptidase IIAndrogenAntigenProstateUrologyInternal medicine

MeSH terms

Androgen AntagonistsAntigens, NeoplasmAntigens, SurfaceDipeptidasesHumansMaleOrchiectomyProstatic NeoplasmsTumor Cells, CulturedUp-RegulationProstate-Specific AntigenGlutamate Carboxypeptidase IICulture Techniques

Citations

627

FWCI

11.98

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases